J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 2098KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 93(9): 952-955, 1992

Report on the annual meeting

EVALUATION OF IMMUNOREACTIVITY TO erbB-2 PROTEIN AS A MARKER OF PROGNOSIS IN BILE DUCT CARCINOMA

Second Department of Surgery, Nagasaki University School of Medicine, Nagasaki, Japan

Koichi Motojima, Kyo Komuta, Atsumori Hiasa, Takahito Tsuribune, Takaki Hashimoto, Tsukasa Tsunoda, Takashi Kanematsu

Recent studies of erbB-2 expression have shown that the erbB-2 oncoprotein correlated with poor prognosis of patients with breast cancer. Surgical treatment of the bile duct carcinoma is currently unsatisfactory. To evaluate erbB-2 oncoprotein as a marker of prognosis, we analyzed 68 bile duct carcinomas immunohistologically, using monoclonal antibody against erbB-2 oncoprotein, as well as clinicopathological data and outcome.
High incidence of expression of erbB-2 oncoprotein was shown in bile duct carcinoma. Positive rates of erbB-2 oncoprotein correlated with stage of bile duct carcinoma. Survival of patients with erbB-2 expression cancer was shorter than those without erbB-2 expression cancer and erbB-2 expression has a prognostic value in bile duct carcinoma.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.